Debunking 7 Myths That Hamper the Realization of Randomized Controlled Trials on Intra-Arterial Thrombolysis for Acute Ischemic Stroke | Zendy

Alfonso Ciccone | Zendy; Luca Valvassori | Zendy; Roberto Gasparotti | Zendy; Francesco Scomazzoni | Zendy; Elena Ballabio | Zendy; Roberto Sterzi | Zendy

Open Access

Debunking 7 Myths That Hamper the Realization of Randomized Controlled Trials on Intra-Arterial Thrombolysis for Acute Ischemic Stroke

Author(s) -

Alfonso Ciccone,

Luca Valvassori,

Roberto Gasparotti,

Francesco Scomazzoni,

Elena Ballabio,

Roberto Sterzi

Publication year - 2007

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.106.465567

Subject(s) - thrombolysis , medicine , stroke (engine) , randomized controlled trial , cardiology , intensive care medicine , radiology , myocardial infarction , mechanical engineering , engineering

Although intravenous (IV) thrombolysis is the standard treatment for patients with ischemic stroke occurring within 3 hours from symptom onset, a few interventional neuroradiologists have been treating this category of patients by an intra-arterial (IA) route for >25 years. However, evidence is still required to support the clinical feeling that IA treatment, which needs longer time and greater complexity, leads to a better outcome. Therefore, the objective of the present review was to analyze beliefs and myths underlying the selection of patients for IA thrombolysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research